Author: Ravi Shankar

Southfield, Michigan, Oct. 22, 2026 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that we expect to issue a news release with our third quarter 2026 earnings on Thursday, October 29, 2026, after the market closes. A webcast is scheduled for Thursday, October 29, 2026, at 5:00 p.m. Eastern Time to discuss third quarter 2026 earnings.  

Conference Call and Webcast Information:
Date: Thursday, October 29, 2026
Time: 5:00 p.m. Eastern Time

Telephone Access: 

Only persons accessing the webcast by telephone will be able to pose questions to the presenters during the webcast. To participate by telephone, you must pre-register using the following link:

https://register-conf.media-server.com/register/BIb09f4d3694a2478ba3f752ee48d8fc50

or through the link posted on the “Investor Relations” section of our website at ir.creditacceptance.com. Upon registering you will be provided with the dial-in number and a unique PIN to access the webcast by telephone.

Webcast Access:
The webcast can also be accessed live by visiting the “Investor Relations” section of our website at ir.creditacceptance.com.

Additionally, a replay and transcript of the webcast will be archived in the “Investor Relations” section of our website.

Description of Credit Acceptance Corporation

We make vehicle ownership possible by providing innovative financing solutions that enable automobile dealers to sell vehicles to consumers regardless of their credit history. Our financing programs are offered through a nationwide network of automobile dealers who benefit from sales of vehicles to consumers who otherwise could not obtain financing; from repeat and referral sales generated by these same customers; and from sales to customers responding to advertisements for our financing programs, but who actually end up qualifying for traditional financing.

Without our financing programs, consumers are often unable to purchase vehicles or they purchase unreliable ones. Further, as we report to the three national credit reporting agencies, an important ancillary benefit of our programs is that we provide consumers with an opportunity to improve their lives by improving their credit score and move on to more traditional sources of financing. Credit Acceptance is publicly traded on the Nasdaq Stock Market under the symbol CACC. For more information, visit creditacceptance.com.

CONTACT: Investor Relations: Jay Brinkley
Senior Vice President & Treasurer
(248) 353-2700 Ext. 6739
IR@creditacceptance.com

JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY 10036.

The event will include presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza and other members of the Ligand senior management team. Presentations will highlight the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. Wes Kaupinen, Founder and CEO of Palvella Therapeutics, a Ligand partner, will be a guest speaker at the event and discuss the progress of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), which is in development for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, clinically significant angiokeratomas, and additional rare disease indications.

A live webcast of the event will be accessible through Ligand’s Investor Relations Events Page. A webcast replay will be available following the conclusion of the event.

Investors and analysts can register for the event here.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results before the opening of the market on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 27870. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika’s website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika

Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our primary focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
investorrelations@anika.com

MIDLAND, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Big Digital Energy, Inc. (“We,” “Big Digital” or the “Company”) (Nasdaq: “BGDE”), a developer and operator of next-generation digital infrastructure, today announced that it will hold its earnings conference call and webcast for the third quarter ended September 30, 2026 on Thursday, November 5^th, 2026 at 5:00 PM Eastern Time. A press release detailing these results will be issued prior to the call on the same day.

Conference Call Information:
To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call.

• Date: November 5, 2026
• Time: 5:00 PM EDT
• Participant Call Links:
  • Live Webcast: Link
  • Dial-in:
    • Toll-Free: (800) 715-9871
    • Toll: (646) 307-1963
    • Passcode: 9283304

A live and archived webcast of the conference call will be available on the Investors section of Big Digital Energy’s website at https://www.bigdigital.energy/.

About Big Digital Energy, Inc.
Big Digital Energy, Inc. (Nasdaq: “BGDE”) is a U.S.-based technology company that designs, builds, and operates next-generation digital infrastructure platforms. The Company provides services spanning artificial intelligence (“AI”), high-performance computing (“HPC”), digital assets (including Bitcoin mining), and other intensive compute applications. The Company delivers both self-mining operations and colocation/hosting for enterprise customers, with a vertically integrated infrastructure model built for scalability and efficiency.

A core part of the Company’s strategy is identifying and advancing sites positioned to support high-performance compute with the infrastructure required for long-term deployment. With approximately 169 megawatts of energized capacity and additional capacity under development, the Company is positioning itself as a competitive provider of digital infrastructure solutions to support the demand for AI data centers.

CONTACT
Investor Relations: IR@bigdigital.energy
Partnerships: Partnerships@bigdigital.energy
Media and Press: mediarelations@bigdigital.energy
Website: www.bigdigital.energy

WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor Contact: 
Justine Koenigsberg
investors@kymeratx.com
857-285-5300 

Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — AMC Global Media Inc. (NASDAQ: AMCX) will host a conference call to discuss results for the third quarter 2026 on Monday, November 9, 2026 at 4:30 p.m. Eastern Time. AMC Global Media will issue a press release reporting its results after the market closes.

The conference call will be webcast live via the company’s website at investors.amcglobalmedia.com.

To access the conference call via telephone, please pre-register for the call to obtain the dial-in number and a passcode.
Pre-registration instructions can be found at investors.amcglobalmedia.com under the heading “Events and Presentations.”

Internet replays will be available at investors.amcglobalmedia.com approximately two hours after the call ends.

About AMC Global Media

AMC Global Media (Nasdaq: AMCX) is home to many of the greatest stories and characters in TV and film and the premier destination for passionate and engaged fan communities around the world. The Company creates and curates celebrated series and films across distinct brands and makes them available to audiences everywhere. Its portfolio includes targeted streaming services AMC+, Acorn TV, Shudder, Sundance Now, HIDIVE and All Reality; cable networks AMC, BBC AMERICA (which includes U.S. distribution and sales responsibilities for BBC News), IFC, SundanceTV and We TV; and film distribution label Independent Film Company. The Company also operates AMC Studios, its in-house studio, production and distribution operation behind acclaimed and fan-favorite original franchises including The Walking Dead Universe and the Anne Rice Immortal Universe. AMC Global Media is headquartered in the United States, with international operations in Iberia, Latin America, Central Europe, the U.K., Australia and New Zealand.

Contacts

Investor Relations		Corporate Communications
Nicholas Seibert		Georgia Juvelis
nicholas.seibert@amcglobalmedia.com		georgia.juvelis@amcglobalmedia.com

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026.

Denali’s management will host a conference call and webcast on Tuesday, November 3, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss third quarter 2026 financial results and provide a general business update.

The live webcast, along with a slide presentation, may be accessed through the Investors section of Denali’s website at www.denalitherapeutics.com or by clicking here. A replay of the webcast will be archived on Denali’s website for a limited time following the call.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Investor Contact:
Laura Hansen
hansen@dnli.com

Presentation and live Q&A to be held after market close on Thursday, November 12, 2026

BOSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) — Merlin, Inc. (Nasdaq: MRLN) today announced that it has plans to host a presentation and Q&A session reviewing business performance for its third quarter ended September 30, 2026, on Thursday, November 12, 2026 beginning at 4:30 p.m. ET.

A registration link for the webcast is available here as well as on our investor relations website at https://investors.merlinlabs.com. A replay of the call and the presentation materials will be available on Merlin’s investor relations website following the call.

About Merlin
Merlin is an aerospace and defense technology company building the operating system of record for autonomous flight. Through a first-principles approach, the company is redefining what’s possible across aviation, aerospace, and defense with the goal of delivering full-stack autonomy for any aircraft, military or civilian, from takeoff to touchdown. The Merlin Pilot system powers a growing range of aircraft and mission profiles, proven through hundreds of autonomous flights from test facilities across the globe. With $100M+ total in IDIQ contract ceiling value under its C-130J autonomy program with USSOCOM, Merlin is advancing American leadership in autonomous aviation by helping to solve national security challenges through safe, reliable autonomy. To learn more, visit www.merlinlabs.com or follow us on X @merlinaero.

Contacts
Investor Relations: investor.relations@merlinlabs.com
Media: media@merlinlabs.com

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ^®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (“IREN”) will release its financial results for the quarter ended September 30, 2026, on Thursday, November 5, 2026 and host a conference call at 5:00 p.m. Eastern Time.

A live audio webcast of the conference call can be accessed at IREN’s Investor Relations website: iren.com/investors. A replay of the webcast will be accessible shortly after the call.

About IREN

IREN is a vertically integrated AI Cloud platform, delivering data centers, compute and software for AI training and inference. IREN’s platform is underpinned by its expansive portfolio of land and grid-connected power in renewable-rich regions across North America, Europe and APAC.

Contacts

Investors
ir@iren.com

Media
media@iren.com